Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on June 4, 2021. The filing reports the entry into a material definitive agreement regarding a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $15,000,000.
- Securities Issued: 3,076,923 shares of common stock and warrants to purchase 1,538,461 shares.
- Offering Price: $4.875 per unit (one share and 0.50 warrants).
- Placement Agent Fee: 7% of gross proceeds, totaling $1,050,000 (calculated from $15M gross proceeds).
- Warrant Terms: Exercise price of $6.09 per share; exercisable starting six months after issuance; expiration five years after the initial exercise date.
- Beneficial Ownership Limitation: Warrant exercise is limited to prevent holders from owning more than 4.99% (or up to 9.99% at election) of outstanding shares.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or cash flow) as it is a current report on a specific transaction rather than a periodic financial statement. The primary material change is the immediate increase in authorized and outstanding equity capital resulting from the sale of the securities.
Outlook, Risks, and Management Commentary
The Company intends to use the net proceeds from the offering for general corporate purposes, including advancing its clinical development programs, though specific allocation details are not provided in this text. The transaction is subject to customary closing conditions. The filing notes that the offering is made pursuant to an effective shelf registration statement on Form S-3.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting all offering expenses.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Confirm the exact number of shares outstanding post-offering to calculate the dilution impact accurately.
- Check the press release (Exhibit 99.1) for management's specific intended use of proceeds.